×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: GXY

Commodities / Markets / Shares

Material Matters: Copper, Lithium & Closures

March 27, 2020March 27, 2020 - by Eva Brocklehurst

A glance through the latest expert views and predictions about commodities. Base metals; cost curves; lithium; and mine closures.

Read More
Commodities / Shares

Lithium Producers In A Holding Pattern

February 24, 2020 - by Eva Brocklehurst

Amid a lack of certainty about when lithium prices will improve Australian spodumene producers are continuing to curtail production.

Read More
Broker News

GXY – Morgan Stanley rates the stock as Equal-weight

January 24, 2020 - by Broker News

Costs disappointed Morgan Stanley in the December quarter, affected by the DMS trials that were called off. 2020 production guidance is lower than previously outlined.

Read More
Commodities / Shares

Behind The Lithium Market Meltdown

September 19, 2019September 19, 2019 - by Tim Boreham

The stronger-for-longer lithium story is not exactly panning out as such, with a global oversupply emerging and the upbeat blue sky stories supplanted by tales of woe from the emerging producers. The same thing’s happening with that other wonder battery metal, graphite.

Read More
Broker News

GXY – Citi rates the stock as Buy

May 17, 2019 - by Broker News

Galaxy Resources has made a strategic equity investment of $22.5m in Alliance Mineral ((A40)). This takes its holding to 12%. Alliance Mineral is currently ramping up the Bald Hill lithium project in Western Australia and has guided to production of 240,000t of spodumene concentrate in FY20.

Read More
Broker News

GXY – UBS rates the stock as Buy

January 25, 2019 - by Broker News

Grade, recoveries and production all rose in the December quarter after a weak September quarter. Guidance for 2019 is below UBS forecasts, with the company targeting first quarter spodumene production of 40-45,000t, and 180-210,000t in 2019.

Read More
Broker News

GXY – Morgan Stanley rates as Equal-weight

August 29, 2018September 6, 2018 - by Broker News

The company has executed a binding agreement with POSCO to sell a package of tenements on the northern basin of Salar del Hombre Muerto for US$280m. Morgan Stanley suggests the deal could add around $0.90 per share to its base case valuation.

Read More
Broker News

GXY – Morgan Stanley rates as Equal-weight

June 29, 2018 - by Broker News

A review of Morgan Stanley’s commodity deck has driven upgrades for metals and bulks while earnings estimates for lithium players are reduced. The market cap weighted downside of -6% drives the broker’s industry view to In-Line from Attractive.

Read More
Broker News

GXY – UBS rates the stock as Buy

June 4, 2018 - by Broker News

The company has updated the definitive feasibility study for the Sal de Vida project and announced the sale of the northern tenements to help fund its development.

Read More
Fn Arena News

Galaxy Finds Solution To Brine Project Funding

May 31, 2018 - by Eva Brocklehurst

Galaxy Resources ((GXY)) has found a neat solution to its funding needs for the Sal de Vida lithium brine project in Argentina, brokers observe. The company has entered a non-binding agreement with POSCO to sell 28% of the Sal de Vida measured and indicated (M&I) resource for US$280m. This will enable Galaxy to largely fund development of the broader portfolio.

Read More
Shares

Galaxy Resources Jumps On Acreage Sale

May 30, 2018 - by Glenn Dyer

Lithium miner, Galaxy Resources surprised yesterday by selling off some of its South American acreage, a move the market loved, sending the shares up 18% at one stage in trading before they settled back to close the day 14.3% higher at $3.42.

Read More
Commodities

Lepidico Lures Investors Into A New Galaxy Where Lithium Is Free

October 20, 2017September 14, 2018 - by Barry Fitzgerald

No one much cared earlier this year when there was a particularly nasty takeover battle between Lithium Australia (LIT) as the suitor and Lepidico (LPD) as the target.

Read More
Shares

Lithium Play Galaxy Hits 8-year High On Q3 Numbers

October 18, 2017 - by Glenn Dyer

Shares lithium producer Galaxy Resources surged and sagged yesterday in the wake of the release what was on the whole an encouraging production report for the three months to September.

Read More
Broker News

GXY – Macquarie rates the stock as Outperform

August 31, 2017 - by Broker News

First half loss of $6.5m compares with Macquarie’s expectations for break-even. The result represented two months of commercial production from Mount Cattlin.

Read More
  • US Political Protests, Inflation and Rising Bond Yields
  • Huge Week for Netflix as Shares Touch Record High
  • Is it Time to Buy Airports and Toll Road Companies?
  • Little to Cheer About as Xmas Retail Spending Slumps
  • Evening Report: ASX eases into the weekend
  • CCL Slightly Exceeds Expectations but Indonesia Still a Worry
  • COVID Still Driving FPH Revenue as Earnings Surge
  • RMD – UBS rates the stock as Buy

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.